文献速递产科

药物干预用于管理胎盘滞留:随机试验的系统评价与Meta分析

Pharmacologic intervention for the management of retained placenta: a systematic review and meta-analysis of randomized trials.
PubMed 文献 · Am J Obstet Gynecol · 2020-06-25

该系统评价与Meta分析纳入29项随机对照试验共2682名受试者,评估药物干预对胎盘滞留的疗效。与安慰剂或对照相比,催产素经脐静脉注射、前列腺素类药物和硝酸甘油在主要结局上呈有利趋势,卡贝缩宫素和前列腺素类药物优于催产素。药物干预组估计失血量较低,但产后出血或输血需求无差异。

要点

  • 卡贝缩宫素和前列腺素类药物在减少人工剥离胎盘或刮宫需求上优于催产素。
  • 与安慰剂或对照相比,药物干预组估计失血量较低,平均差为121.5 mL(95%CI,-185.7至-52.3)。
  • 药物干预与安慰剂或对照在产后出血或输血需求上无差异。

核心结论

  • 催产素经脐静脉注射、前列腺素类药物和硝酸甘油的合并估计在胎盘滞留管理上优于安慰剂或对照。
  • 卡贝缩宫素和前列腺素类药物在减少人工剥离或刮宫需求上优于催产素。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、ClinicalTrials.gov、Cochrane Library、Web of Science和Scopus,无发表日期限制,仅纳入随机对照试验。
  • 共纳入29项随机对照试验,2682名受试者。
  • 使用Cochrane协作组偏倚风险评估工具评价纳入文献质量,基于随机效应和固定效应分析估计合并风险比,研究间异质性以I²≥50%考虑。

主要发现

  • 最常用药物为经脐静脉注射催产素,这些研究间存在高度异质性(I²=62%)。
  • 催产素在主要结局上劣于卡贝缩宫素(风险比1.61;95%CI,1.03-2.52)和前列腺素类药物(风险比2.63;95%CI,1.18-5.86)。
  • 对于催产素、前列腺素类药物和硝酸甘油,在主要结局上呈有利于研究药物的趋势, compared with 对照或安慰剂。
  • 与安慰剂或对照相比,药物干预组估计失血量较低,平均差为121.5 mL(95%CI,-185.7至-52.3)。
  • 药物干预与安慰剂或对照在产后出血或输血需求上无差异。

关键数值与推荐

  • 主要结局为需要人工剥离胎盘或刮宫。
  • 催产素 vs 卡贝缩宫素:风险比1.61(95%CI,1.03-2.52),催产素劣于卡贝缩宫素。
  • 催产素 vs 前列腺素类药物:风险比2.63(95%CI,1.18-5.86),催产素劣于前列腺素类药物。
  • 药物干预 vs 安慰剂或对照:估计失血量平均差121.5 mL(95%CI,-185.7至-52.3),药物干预组较低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 经脐静脉注射催产素的研究间存在高度异质性(I²=62%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Retained placenta affects 2% to 3.3% of all vaginal deliveries and is one of the leading causes of postpartum hemorrhage worldwide. Despite the prevalence of this condition, there is limited guidance on its management. OBJECTIVE: A systematic review and meta-analysis were performed to evaluate the efficacy of pharmacologic interventions for the management of retained placenta. STUDY DESIGN: PubMed, ClinicalTrials.gov, Cochrane Library, Web of Science, and Scopus were searched for full-text publications in English. Search terms included "retained placenta" AND "treatment" OR "therapy" OR "disease management" OR "Pitocin" OR "misoprostol" OR "Cytotec" OR "dinoprostone" OR "nitroglycerin" OR "carbetocin" OR "ergotamine," with no restriction on publication dates. Only randomized controlled trials were included. The primary outcome was the need for manual extraction of the placenta or dilation and curettage. Reviewers evaluated the quality of included articles using the Cochrane Collaboration's tool for assessing the risk of bias. Pooled risk ratios were estimated based on random- and fixed-effects analyses. Interstudy heterogeneity was considered when I2≥50%. RESULTS: The literature search identified 29 randomized controlled trials that met the inclusion criteria (2682 subjects). The most commonly used agent across the studies was oxytocin administered via umbilical vein injection; there was high heterogeneity among these studies (I2=62%). Oxytocin was inferior to carbetocin (risk ratio, 1.61; 95% confidence interval, 1.03-2.52) and prostaglandins (risk ratio, 2.63; 95% confidence interval, 1.18-5.86) for the primary outcome. For oxytocin, prostaglandin agents, and nitroglycerin, there was a trend toward favoring the study drug for the primary outcome compared with control or placebo. Compared with placebo or control, estimated blood loss was lower if pharmacologic interventions were administered, with a mean difference of 121.5 mL (95% confidence interval, -185.7 to -52.3). There was no difference in postpartum hemorrhage or the need for blood transfusion between pharmacologic interventions and placebo or control. CONCLUSION: Pooled estimates for oxytocin via umbilical vein injection, prostaglandin agents, and nitroglycerin performed favorably compared with placebo or control for the management of retained placenta. Carbetocin and prostaglandin agents were superior to oxytocin in reducing the need for manual extraction or dilation and curettage.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Patrick HS, Mitra A, Rosen T, et al. Pharmacologic intervention for the management of retained placenta: a systematic review and meta-analysis of randomized trials. Am J Obstet Gynecol. 2020. PMID: 32592695. doi:10.1016/j.ajog.2020.06.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。